Skip to content
中文产业新闻评分60Chinese source

恒瑞HER2 ADC瑞康曲妥珠单抗II期研究在唾液腺癌HER2高表达人群ORR达91.7%

高表达人群ORR达91.7%！恒瑞ADC创新药瑞康曲妥珠单抗治疗晚期唾液腺癌HER2分层II期研究荣登JCO

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.